Signals, Powered By EquityPandit
Dr Reddy’s Laboratories has got 13 observations from the US health regulator for its formulation manufacturing facility at Duwada, Vishakhapatnam.
Dr Redd’s Laboratories has said in a BSE filing that “The audit of company’s formulation manufacturing facility at Duwada, Vishakhapatnam, by the US FDA, has been completed on March 8, 2017. The company have been issued a Form 483 with 13 observations, which the company is addressing.”
However, the company did not specify the observations.
